Prospects for the use of immunotherapy in the treatment of head and neck squamous cell carcinoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Head and neck squamous cell carcinoma (HNSCC) takes sixth place in the structure of morbidity and eighth place in the mortality structure of patients with malignant neoplasms worldwide. A potential new therapeutic approach for treating recurrent and/or metastatic HNSCC is immunotherapy targeting immune checkpoints, such as type 1 programmed death receptor (PD-1). The review presents the results of studies of the efficacy and safety of drugs for immunotherapy of recurrent and/or metastatic HNSCC (pembrolizumab, nivolumab, etc.). The prospects of neoadjuvant immunotherapy for advanced HNSCC are discussed. Recent studies of immunotherapy with immune checkpoint inhibitors confirm the appropriateness of using this approach, based on significantly higher tumor control and life expectancy compared to standard methods of treating patients with HNSCC.

Full Text

Restricted Access

About the authors

V. A Zagoruyko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. Yu Semiglazova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

Email: tsemiglazova@mail.ru
Dr. Sci. (Med.), Associate Professor, Head of the Division - Leading Reseacher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology; Professor at the Department of Oncology, North-Western State Medical University n.a. I.I. Mechnikov 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation

Z. A.-G Radzhabova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. V Tkachenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. M Teletaeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Kh Latipova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. I Semenova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

V. V Semiglazov

N.N. Petrov National Medical Research Center of Oncology; Pavlov University

St. Petersburg, Russia

L. V Filatova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

References

  1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;3(4):524-48. doi: 10.1001/jamaoncol.2016.5688.
  2. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г. В. Петровой. М, 2018. 30 c.
  3. Gillison M.L., D'Souza G., Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J National Cancer Institute. 2008;100(6):407-20. doi: 10.1093/jnci/djn025.
  4. Hashibe M., Brennan P, Chuang S.C., Boccia S. Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international head and neck cancer Epidemiology consortium. Cancer Epidemiology Biomarkers and Prevention 2009;18(2):541-50. doi: 10.1158/1055-9965.EPI-08-0347.
  5. Parfenov M., Pedamallu C.S., Gehlenborg N., et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(43):15544-549. Doi: 10.1073/ pnas.1416074111.
  6. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine. 2002;8(8):793-800. doi: 10.1038/nm730.
  7. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;176(1):139-48.
  8. Vermorken J.B., Specenier P Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(suppl. 7):252-61. doi: 10.1093/annonc/mdq453.
  9. National Comprehensive Cancer Network I. NCCN Clinical Practice Guidelines. Head and Neck Cancers. PET-CT: A Case-Based Approach. 2020;1:124-45.
  10. Schalper K.A., Venur V.A., Velcheti V. Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: Current insights. J Receptor, Ligand Channel Res. 2015;8:1-7.
  11. Cho YA. Yoon H.J., Lee J.Il, et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncology. 2011;47(12):1148-53. doi: 10.1016/j.oraloncology.2011.08.007.
  12. Parry R.V, et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Mol Cell Biol. 2005;25:301-5. doi: 10.1128/ MCB.25.21.9543-9553.2005.
  13. Saada-Bouzid E., Defaucheux C. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma. Elsevier science. 2017;27(5):5-6.
  14. Seiwert T.Y., Burtness B., Mehra R., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-65. doi: 10.1016/S1470-2045(16)30066-3.
  15. Chow L.Q.M., Haddad R., Gupta S., et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838-45. Doi: 10.1200/ JCO.2016.68.1478.
  16. Tahara M., Muro K., Hasegawa Y., et al. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. Cancer Science. 2018;109(3):771-76. doi: 10.1111/cas.13480.
  17. Bauml J., Seiwert T.Y., Pfister D.G., et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542-49. Doi: 10.1200/ JCO.2016.70.1524.
  18. Cohen E.E.W., Soulieres D., Tourneau C.Le, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-67. doi: 10.1016/S0140-6736(18)31999-8.
  19. Burtness B., Harrington K.J., Greil R., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28. Doi: 10.1016/ S0140-6736(19)32591-7.
  20. Ferris R.L., Blumenschein G. Jr., Fayette J., et al. Nivolumab for Recurrent SquamousCell Carcinoma of the Head and Neck. N Engl J Med. 2016:1856-67. Doi: 10.1056/ NEJMoa1602252.
  21. Ferris R.L., Blumenschein G. Jr., Fayette J., et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;68:45-51. doi: 10.1016/j.oraloncology.2018.04.008.
  22. Hanna G.J., Lizotte P., Cavanaugh M., et al. Frameshift even ts predict anti-PD-1/L1 response in head and neck cancer. JCI insight. 2018;3(4):1-13.
  23. Pai S.I., Zandberg D.P, Strome S.E. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol. 2016;61:152-58. Doi: 10.1016/j. oraloncology.2016.08.001.
  24. Siu L.L., Even C., Mesa R., et al. Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/ Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2018;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.
  25. Zandberg D.P, Algazi A.P, Jimeno A., et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142-52. doi: 10.1016/j.ejca.2018.11.015.
  26. Colevas A.D., Bahleda R., Braiteh F. Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial. Ann Oncol. 2018;29(11):2247-53. Doi: 10.1093/ annonc/mdy411.
  27. Lefebvre J.L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial. J National Cancer Institute. 1996;88(13):890-99. doi: 10.1093/jnci/88.13.890.
  28. Melero I., Berraondo P., Rodrguez-Ruiz M.E., Perez-Gracia J.L. Cancer Making the most of cancer surgery with neoadjuvant immunotherapy. Cancer Discov. 2016;6(12):1312-14. doi: 10.1158/2159-8290.CD-16-1109.
  29. Uppaluri R., Zolkind P, Lin T., Nussenbaum B. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2017;35(15 suppl.):6012. doi: 10.1200/JCO.2017.35.15_suppl.6012.
  30. Suzanne L.T., Shailender B., et al. Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358. J Clin Oncol. 2018;36(15):1. doi: 10.1200/JCO.2018.36.15_suppl.9505.
  31. Taube J.M., Klein A., Brahmer J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. 2014. 5064-5074 p.
  32. Zandberg D.P, Strome S.E. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(7):627-32. Doi: 10.1016/j. oraloncology.2014.04.003.
  33. Seiwert T.Y., Burtness B., et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1 + head and neck cancer patients. J Clin Oncol. 2017;33(15):5-6.
  34. Economopoulou P., Kotsantis I., Psyrri A. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Curr Treat Options Oncol. 2016;17(8):2-5.
  35. Masucci G.V., Cesano A., Hawtin R., et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I -pre-analytical and analytical validation. J ImmunoTher Cancer. 2016;4(1):2-25. doi: 10.1186/s40425-016-0178-1.
  36. Yearley J.H., Gibson C., Yu N., et al. PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158-67. doi: 10.1158/1078-0432.CCR-16-1761.
  37. Ayers M., Lunceford J., Nebozhyn M. IFN-Y-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):5-9.
  38. Chow L.Q.M., Mehra R., Haddad R, et al. Recurrent. Metastatic Head and Neck Squamous Biomarkers and Response to Pembrolizumab in Cell Carcinoma. Clin Oncol. 2016;15:15-17.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies